Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma
- 1 May 1978
- journal article
- case report
- Published by Wiley in Annals of Neurology
- Vol. 3 (5) , 441-444
Abstract
An unusual neurological syndrome occurred in 4 of 158 patients treated for osteogenic sarcoma with combination chemotherapy. There was an abrupt onset of focal cerebral deficits approximately ten days after chemotherapy with vincristine and high‐dose methotrexate plus citrovorum factor rescue. The syndrome was short lived and always occurred early in the course of treatment. Prolonged neurological deficits remained in 2 patients. When similar chemotherapy was reinstituted in the 4 patients, no further neurological complications ensued. Possible causes include a leukoencephalopathy related to methotrexate or an embolic cerebral vasculopathy related to necrotic tumor microemboli emanating from the lungs.Keywords
This publication has 11 references indexed in Scilit:
- Chemotherapy of acute lymphoblastic leukemia in childrenAmerican Journal of Hematology, 1976
- Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcomaCancer, 1975
- The central nervous system in childhood leukemia.II. Subacute leukoencephalopathyCancer, 1975
- Pontine Glioma1974
- Pontine glioma. High-dose methotrexate and leucovorin rescue1974
- Neurotoxicity of Commonly Used Antineoplastic AgentsNew England Journal of Medicine, 1974
- Paraplegia following intrathecal methotrexateThe Journal of Pediatrics, 1973
- Necrotizing Encephalopath Following Intraventricular Instillatio of MethotrexateArchives of Neurology, 1973
- Encephalopathy in Acute Leukaemia Associated with Methotrexate TherapyArchives of Disease in Childhood, 1972
- Clinical Investigations in the Treatment of Meningeal Leukemia: Radiation Therapy Regimens vs. Conventional Intrathecal MethotrexateBlood, 1969